Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07488819 · ClinicalTrials.gov registry record
Imaging Phosphodiesterase 4B (PDE4B) in People With Psychiatric Disorders With Positron Emission Tomography (PET) and the Radiotracer [18F]PF974
A clinical trial, sponsored by Yale University.
- Recruiting
- Registry status
- 160
- Enrollment target
NCT07488819: Recruiting study, sponsored by Yale University.
NCT07488819 is a clinical trial that is actively recruiting participants, run by Yale University. The registered enrollment target is 160 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07488819 is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- 160 participants
- Enrollment target
Study Summary
Imaging PDE4B in people with psychiatric disorders with PET and the radiotracer \[18F\]PF974
Primary Outcome
proportional to the levels of PDE4B available for radiotracer binding
Interventions
- DRUG PF974
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-07-07 |
| Est. Completion | 2032-03-01 |
What NCT07488819 shows while recruiting
NCT07488819 is an observational study that tracks outcomes without assigning an intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which PF974 is the first listed.
NCT07488819 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07488819 about?
NCT07488819 is a clinical study titled "Imaging Phosphodiesterase 4B (PDE4B) in People With Psychiatric Disorders With Positron Emission Tomography (PET) and the Radiotracer [18F]PF974". Imaging PDE4B in people with psychiatric disorders with PET and the radiotracer \[18F\]PF974
What is the current status of trial NCT07488819?
This trial is currently recruiting. The enrollment target is 160 participants. The study started on 2025-07-07. Estimated completion is 2032-03-01.
What interventions are being tested in trial NCT07488819?
The interventions under investigation include: PF974 (DRUG).
Who is sponsoring clinical trial NCT07488819?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI